At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Axitinib +3 moredrug
Likely dose
Axitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients With Stage III Malignant Melanoma
In Brief
A Phase 2 clinical trial evaluating therapeutic conventional surgery, laboratory biomarker analysis, and 2 other interventions for Melanoma and 4 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartDec 2011
Primary CompletionDec 2016
TodayJul 2026
First PostedMar 23, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 15.3 years ago
Interventions
therapeutic conventional surgeryprocedure
Undergo surgery
laboratory biomarker analysisother
Correlative studies
Axitinibdrug
Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
pharmacological studyother
Correlative studies